Product Development and Clinical trials
Pneoterik was incorporated on 7th December 2020, at the peak of the COVID-19 pandemic—a period marked by unprecedented loss of human life globally. Among the most painful casualties were doctors, paramedics, and healthcare workers who risked their lives serving infected patients and ultimately succumbed to airborne and hospital-acquired infections.
Simultaneously, hospitals witnessed a disturbing rise in fungal and nosocomial infections, especially among post-COVID patients. These realities exposed a critical gap in hospital infection-control infrastructure and became the triggering force behind Pneoterik’s formation.
R&D Foundation and Scientific Validation
With support from the leading technology institutes and subject matter experts—including Mr. R.Shankar, Mr. Venkateswaran Harihara, Mr. N.Narayan, Mr. BG Venkatachalam, and a dedicated team of doctors—the Pneoterik team undertook extensive research to develop advanced solutions aimed at protecting patients, doctors, paramedics, and patient attenders from airborne microbes and hospital-acquired infections.
The outcome was a set of highly scientific, uniquely designed air purification and infection-control products with exceptional performance and a differentiated delivery mechanism. Given the complexity and novelty of the technology, development demanded:
- Multiple stages of scientific testing and validation
- Extensive documentation and compliance protocols
- Development of multiple configurations to address real hospital challenges
Product Portfolio Evolution
Driven by on-ground hospital needs, Pneoterik developed a comprehensive range of solutions, including:
- Positive Pressure Enclosures
- Negative Pressure Enclosures
- Portable Plug-and-Play Solutions
- Sterile 360
- Sterile TVOC 360(Total Volatile Organic Compounds)
Each solution was engineered to address specific hospital environments such as ICUs, OTs, isolation rooms, and infection-control zones.
Live Trials, Installations & Clinical Evidence
Before commercializing the products at scale, Pneoterik intentionally invested time and capital to establish real-world proof and regulatory readiness. This included:
Live running installations with continuous digital IAQ monitoring
24/7 cloud-based monitoring systems
Long-duration real-time data capture for documentation
Installations were successfully conducted at leading hospitals including:
Apollo Hospitals, Chennai
Fortis Hospitals
VHS Hospitals
Jayadeva Hospitals, Bengaluru
MS Ramaiah & several others across India
Key Study Outcomes
- Zero microbial growth for continuous 48 days of operation
- Post-operative hospitalization reduced from 3.5 days to 2.5 days, a critical outcome with strong relevance for:
- HAI Reduction From 1.6% average to 0%
- Hospitals
- Insurance companies
- Healthcare economics
These outcomes significantly strengthen Pneoterik’s value proposition and provide strong scientific backing for adoption.
Infection Prevention & Control Hyderabad
IFCAI Collaborated Research Study
Effect of air purification by Sterile 360 on mean length of stay in hospital
Effect of air purification by Sterile 360 on hospital-acquired infections ( HAIs)
Representative photomicrographs of microbial culture plates of air sampling
Air- born viable pathogen load
Line graph of CO2 concentration in the air during pre-installation phase from 10 Feb 2024 to 09 May2024.
Study Report from Equinox Labs
Sr. No
Parameter
Unit
Reading 1 (0 minute)
Reading 4 (60 minute)
% Reduction After 60 minutes
1
0.3 µm
Particles/m³
27919
196
99.3
2
0.5 µm
Particles/m³
718
4
99.4
13
TPC (Total Plate Count)
Particles/m³
718
4
100
14
Yeast & Mold
Cfu/m3
3
0
100
Equinox Labs Private Limited
CIN No.: U74999MH2017PTC297024 Equinox Center,
R 65, TTC, Rabale, Navi Mumbai – 400701 5 +91
+91 22 6860 9300
info@equinoxlab.com
www.equinoxlab.com
